Don't miss a single story. Get it delivered to your inbox with our daily recap on what's moving the markets.

Khiron Life Sciences (KHRN.V), one of the first medical marijuana companies to be fully-licensed in Colombia, isn’t concerning itself with the Californian cannabis market.

Instead, the company has set its sights on legalized regions outside the U.S. like Latin America and Europe. These markets may not be as big as California and the U.S., but they are sizable, sustainable and more than available in the nascent multi-billion-dollar global weed marketplace.

Equity.Guru’s Chris Parry spoke with Khiron president, Chris Naprawa, to get a bird’s eye view of the company, the international legal cannabis market, the 2018 farm bill and what the capital markets can expect from Khiron over the next 12 months.


Listen in!

Check out our Podbean site and iTunes channel for more great content!

Disclaimer: ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

Chris Parry

Chris Parry is a two-time Webster Award winning journalist who has been featured in the pages of The Vancouver Sun, The Province, National Post, Spin, Hollywood Reporter, FHM, Stuff, and Stockhouse. He was the first business journalist to identify and focus on the move to marijuana as an investment opportunity, and started Equity.Guru as a venue for honest, no punches pulled coverage of the North American public markets.

Leave a Reply

Be the First to Comment!

Notify of